



SEQUENCE LISTING

<110> Peter Harrison

<120> High-Affinity Antibodies

<130> GJE-59

<140> 09/786,015

<141> 2001-02-28

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(363)

<223> Description of Artificial Sequence:Antibody Fragment

<400> 1

cag gtg cag ctg cag gag tcg gga ccc agc ctg gtg aag ccc tca cag 48
Gln Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15

acc ctc tcc ctc acc tgc acg gtc tct gga ttc tca tta acc aag tat 96
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Lys Tyr
20 25 30

ggc gtt agt tgg gtc cgc cag gct cca gga aag gcg ctt gag tgg cta 144
Gly Val Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45

ggc ggt gtg tcc agt ggt gca cta aca gcc tat aac aca gcc cta cag 192

Gly Gly Val Ser Ser Gly Ala Leu Thr Ala Tyr Asn Thr Ala Leu Gln
 50 55 60

tcc cga ctc agc gtc acc agg gac acc tcc aag agc caa ttc tcc ctg 240
 Ser Arg Leu Ser Val Thr Arg Asp Thr Ser Lys Ser Gln Phe Ser Leu
 65 70 75 80

tca ctg agc agc gtg act act gag gac acg gcc att tac tac tgt gcg 288
 Ser Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Ile Tyr Tyr Cys Ala
 85 90 95

aaa tct gtc aat ggt gac agt gtt cct tat ggt ttg gac tac tgg agc 336
 Lys Ser Val Asn Gly Asp Ser Val Pro Tyr Gly Leu Asp Tyr Trp Ser
 100 105 110

cca gga ctc cta ctc acc gtc tcc tca 363
 Pro Gly Leu Leu Leu Thr Val Ser Ser
 115 120

<210> 2

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Antibody
 Fragment

<400> 2

Gln Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Lys Tyr
 20 25 30

Gly Val Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
 35 40 45

Gly Gly Val Ser Ser Gly Ala Leu Thr Ala Tyr Asn Thr Ala Leu Gln
 50 55 60

Ser Arg Leu Ser Val Thr Arg Asp Thr Ser Lys Ser Gln Phe Ser Leu
 65 70 75 80

Ser Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Ile Tyr Tyr Cys Ala
 85 90 95

Lys Ser Val Asn Gly Asp Ser Val Pro Tyr Gly Leu Asp Tyr Trp Ser
 100 105 110

Pro Gly Leu Leu Leu Thr Val Ser Ser
 115 120

<210> 3

<211> 333

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1) .. (333)

<223> Description of Artificial sequence: Antibody Fragment

<400> 3

cag gat gtg ctg act cag ccg tcc tcc gtg tct ggg tcc ctg ggc cag 48
 Gln Asp Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
 1 5 10 15

agg gtc tcc atc acc tgc tct gga agc agc agc aac att gga ggt aat 96
 Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn
 20 25 30

gct tat gtg ggc tgg tac caa cag gtc cca gga tca gcc ccc aga ctc 144
 Ala Tyr Val Gly Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Arg Leu
 35 40 45

ctc atc agt gct aca acc gat cga gcc tcg ggg atc ccc gac cga ttc 192
 Leu Ile Ser Ala Thr Thr Asp Arg Ala Ser Gly Ile Pro Asp Arg Phe
 50 55 60

tcc ggc tcc agg tct ggg aac aca gcc acc ctg acc atc agc tcg ctc 240
 Ser Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu
 65 70 75 80

cag gct gag gac gag gcc gat tat tac tgt gca tcg tat caa agt act 288
 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Gln Ser Thr
 85 90 95

tac agt ggt gtt ttc ggc agc ggg acc agg ctg acc gtc ctg ggt 333
 Tyr Ser Gly Val Phe Gly Ser Gly Thr Arg Leu Thr Val Leu Gly
 100 105 110

<210> 4

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Antibody

<400> 4

Gln Asp Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15

Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn
20 25 30

Ala Tyr Val Gly Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Arg Leu
35 40 45

Leu Ile Ser Ala Thr Thr Asp Arg Ala Ser Gly Ile Pro Asp Arg Phe
50 55 60

Ser Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Gln Ser Thr
85 90 95

Tyr Ser Gly Val Phe Gly Ser Gly Thr Arg Leu Thr Val Leu Gly
100 105 110
